Unichem Laboratories Ltd
Unichem Laboratories Ltd (UNICHEMLAB) last reported results for the quarter ended Jun 2026, with sales of ₹633 crore and net profit of ₹41 crore. The stock last traded at ₹531, a market capitalisation of ₹3,752 crore, on a P/E of 30.7. Over the past 52 weeks the stock has ranged between ₹278 and ₹687. Figures are as of 9 Oct 2026 and are not real time.
Unichem Laboratories Ltd share price and key metrics
- Current price
- ₹531
- Market cap
- ₹3,752 cr
- Stock P/E
- 30.7
- Book value
- ₹386
- ROE
- 3.17%
- ROCE
- 4.13%
- Dividend yield
- 0.00%
- 52w high / low
- 687/278
Metrics as of 9 Oct 2026. Not real time.
Track Unichem Laboratories Ltd
Cruxal reads every Unichem Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Unichem Laboratories Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 12%
- 3 Years
- 18%
- TTM
- 7%
- 10 Years
- -3%
- 5 Years
- 25%
- 3 Years
- 35%
- TTM
- -2%
- 10 Years
- 6%
- 5 Years
- 15%
- 3 Years
- 8%
- 1 Year
- 9%
- 10 Years
- 11%
- 5 Years
- 0%
- 3 Years
- 2%
- Last Year
- 3%
Unichem Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹633 cr, up 20.1% from ₹527 cr a year earlier. Net profit turned positive at ₹41 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 |
| Expenses | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 |
| Operating profit | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 |
| OPM % | 11% | 16% | 14% | 4.3% | 11% | 9% | 8% | 11% |
| Other income | 9 | 14 | 9 | 7 | -37 | 287 | 11 | 16 |
| Interest | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 |
| Depreciation | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 |
| Profit before tax | 27 | 62 | 58 | -9 | -11 | 293 | 19 | 49 |
| Tax % | 9% | 6% | 8% | 16% | 10% | 10% | 42% | 15% |
| Net profit | 25 | 58 | 53 | -10 | -12 | 264 | 11 | 41 |
| EPS (₹) | 3.50 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 5.89 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Unichem Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,785 | 2,111 | 2,202 | 2,308 |
| Operating profit | -41 | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 | 189 | 229 |
| OPM % | -6% | -16% | -6% | -4.5% | 7% | 6% | -3.4% | 4.9% | 13% | 9% | 10% |
| Net profit | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 | 253 | 305 |
| EPS (₹) | 11.96 | 361.82 | -3.38 | -8.55 | 4.87 | 4.70 | -28.72 | -13.32 | 19.53 | 35.91 | 43.29 |
TTM is the trailing twelve months to the most recent quarter.
Unichem Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 1,045 | 2,666 | 2,606 | 2,517 | 2,543 | 2,604 | 2,421 | 2,424 | 2,437 | 2,703 |
| Borrowings | 98 | 151 | 200 | 206 | 119 | 349 | 314 | 248 | 460 | 500 |
| Other liabilities | 359 | 359 | 323 | 407 | 436 | 351 | 444 | 589 | 659 | 489 |
| Total liabilities | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 | 3,707 |
| Fixed assets | 491 | 578 | 810 | 870 | 884 | 990 | 1,257 | 1,252 | 1,300 | 1,213 |
| CWIP | 250 | 238 | 92 | 330 | 568 | 494 | 147 | 123 | 31 | 100 |
| Investments | 14 | 901 | 926 | 550 | 392 | 264 | 2 | 1 | 0 | 0 |
| Other assets | 766 | 1,473 | 1,313 | 1,395 | 1,269 | 1,571 | 1,787 | 1,898 | 2,239 | 2,394 |
| Total assets | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 | 3,707 |
As reported by the company. Total assets equal total liabilities by construction.
Unichem Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 68 | -112 | -328 | 20 | 33 | -260 | -85 | 14 | -7 | 4 |
| Cash from investing | -132 | 1,648 | -286 | -36 | -66 | 100 | 241 | 63 | -242 | 194 |
| Cash from financing | 59 | -881 | -2 | -62 | -121 | 191 | -81 | -106 | 184 | 2 |
| Net cash flow | -4 | 655 | -616 | -78 | -154 | 32 | 75 | -29 | -65 | 200 |
| Free cash flow | -79 | -271 | -519 | -360 | -254 | -386 | -123 | 0 | -142 | 163 |
| CFO / operating profit | -237% | 89% | 424% | -49% | 52% | -350% | 160% | 23% | 4% | 6% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Unichem Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 128% | -2% | -2% | 2% | 1% | -5% | -0% | 6% | 4% |
| Debtor days | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 | 135 | 137 |
| Inventory days | 397 | 278 | 278 | 374 | 518 | 527 | 414 | 365 | 418 | 349 |
| Days payable | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 174 | 164 | 128 |
| Cash conversion cycle | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 322 | 389 | 358 |
| Working capital days | 174 | 133 | 165 | 154 | 163 | 207 | 207 | 173 | 159 | 169 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Unichem Laboratories Ltd shareholding pattern
Promoters held 70.22% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.90% and DIIs 10.46%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% |
| FIIs | 0.94% | 1.05% | 0.98% | 0.98% | 0.99% | 0.99% | 1.00% | 0.90% |
| DIIs | 11.65% | 11.63% | 11.32% | 10.92% | 10.74% | 10.73% | 10.63% | 10.46% |
| Public | 17.17% | 17.11% | 17.47% | 17.88% | 18.04% | 18.05% | 18.14% | 18.41% |
| No. of shareholders | 20,374 | 21,472 | 21,621 | 23,010 | 23,577 | 23,267 | 23,386 | 25,347 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Unichem Laboratories Ltd corporate filings
- Unichem Laboratories reports USFDA inspection at Goa formulation facilityCompany Updatelow impact
Cruxal's analysis: Unichem Laboratories has announced a USFDA inspection at its formulation facility located…
Read the full analysis - Notice of Closure of Trading WindowInsider Trading / SASTlow impact
- Unichem Laboratories Ltd files routine disclosure under Regulation 30 of SEBI (LODR) RegulationsCompany Updatelow impact
Cruxal's analysis: Unichem Laboratories Ltd has submitted a routine disclosure under Regulation 30 of the…
Read the full analysis - Unichem Laboratories Ltd extends exercise period for ESOP 2018 optionsCompany Updatelow impact
Cruxal's analysis: Unichem Laboratories has announced an extension of the exercise period for options…
Read the full analysis - Unichem Laboratories reports significant increase in trading volume of securitiesCompany Updatelow impact
Cruxal's analysis: Unichem Laboratories has disclosed a significant increase in the volume of its traded…
Read the full analysis - Unichem Laboratories Limited announces successful conclusion of 63rd Annual General Meeting and re-appointment of MD & CEOAGM/EGMlow impact
Cruxal's analysis: Unichem Laboratories Limited has successfully concluded its 63rd Annual General Meeting…
Read the full analysis - Unichem Laboratories Reports Q1 FY27 Financial Results with Consolidated Revenue of 632.62 croreCompany Updatehigh impact
Cruxal's analysis: Unichem Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis - Unichem Laboratories Ltd. concludes 63rd Annual General Meeting; re-appoints Pabitrakumar Bhattacharyya as MD & CEOAGM/EGMlow impact
Cruxal's analysis: Unichem Laboratories Ltd. has successfully concluded its 63rd Annual General Meeting held…
Read the full analysis - Unichem Laboratories Reports Strong Q1 FY27 Turnaround with Consolidated PAT of 41.47 croreBoard Meetinghigh impact
Cruxal's analysis: Unichem Laboratories Limited has reported a significant financial turnaround for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.